MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 154 filers reported holding MERSANA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,375,957 | +2636.0% | 418,224 | +3318.0% | 0.00% | – |
| Q1 2023 | $50,290 | -91.2% | 12,236 | -87.5% | 0.00% | -100.0% |
| Q4 2022 | $571,678 | +449.7% | 97,556 | +534.1% | 0.00% | +100.0% |
| Q3 2022 | $104,000 | -90.1% | 15,386 | -93.2% | 0.00% | -83.3% |
| Q2 2022 | $1,046,000 | -46.4% | 226,372 | -53.7% | 0.01% | -25.0% |
| Q1 2022 | $1,951,000 | +370.1% | 488,997 | +633.4% | 0.01% | +700.0% |
| Q4 2021 | $415,000 | -28.1% | 66,672 | +56.8% | 0.00% | -50.0% |
| Q2 2021 | $577,000 | -35.7% | 42,507 | -23.3% | 0.00% | -60.0% |
| Q1 2021 | $897,000 | -25.4% | 55,415 | +22.6% | 0.01% | -44.4% |
| Q4 2020 | $1,202,000 | +227.5% | 45,187 | +129.4% | 0.01% | +80.0% |
| Q3 2020 | $367,000 | -39.5% | 19,695 | -24.1% | 0.01% | -50.0% |
| Q2 2020 | $607,000 | +754.9% | 25,940 | +114.4% | 0.01% | +400.0% |
| Q1 2020 | $71,000 | – | 12,097 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 5,000,000 | $6,350,000 | 1.92% |
| VR Adviser, LLC | 11,328,000 | $14,386,560 | 1.51% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $11,002,865 | 1.23% |
| Affinity Asset Advisors, LLC | 2,850,000 | $3,619,500 | 1.02% |
| EcoR1 Capital, LLC | 19,364,688 | $24,593,154 | 0.83% |
| Altium Capital Management LP | 1,059,136 | $1,345,103 | 0.70% |
| 5AM Venture Management, LLC | 1,305,000 | $1,657,350 | 0.48% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $1,148,420 | 0.38% |
| COMMODORE CAPITAL LP | 2,244,378 | $2,850,360 | 0.33% |
| Philosophy Capital Management LLC | 2,342,634 | $2,975,145 | 0.32% |